CLAIM AMENDMENTS

Claims 1-19 (canceled).

Claim 20 (new): A medical test kit, comprising:

a glucose testing composition having 9.8-17.3 w/v% sodium citrate, 5.3-10.0 w/v% anhydrous sodium carbonate, 1.5-1.73 w/v% copper sulfate and a remaining quantity of distilled water;

a protein testing composition having 9.4-10.5 w/v% salicylic sulfate, 38-50 ml distilled water in 100 ml protein testing composition, 0.5-2.0 w/v% sodium chloride, 1.0-3.0 v/v% anhydrous acetic acid and a remaining quantity of 95% methanol;

a blood testing composition having 0.25-1.0 w/v% benzidine, 40-80 ml acetic acid in 100 ml of said blood testing composition, and a remaining quantity of 95% methanol;

a calcium testing composition having 1.5-2.0 w/v% oxalic acid, 1.5-2.0 w/v% oxalic amide, 3.2-3.5 v/v% acetic acid and a remaining quantity of distilled water; and

a nitrite testing composition having 0.35-0.45 w/v% sulfanilic acid, 0.2-0.3 w/v% α-naphthyl amide, 1.0-2.0 v/v% methanol, 20-40.0 v/v% acetic acid and a remaining quantity of distilled water; and

a first corresponding plurality of interpretation spectra with respect to said glucose testing composition, said protein testing composition, said blood testing composition, said calcium testing composition and said nitrite testing composition respectively, wherein each said testing composition in response to a testing sample reacts to the testing sample for providing a result interpreted by said corresponding interpretation spectrum such that a user is capable of comparing the result and said corresponding spectrum to generate first health condition data.

Claim 21 (new): The medical test kit, as recited in claim 20, further comprising:

a bilirubin testing composition having 0.89-1.2 w/v% acid iron chloride, 20.0-25.3 w/v% acetate chloride, 5.0 ml acetic acid in each 100 ml bilirubin testing composition, and a remaining quantity of distilled water;

a bilinogen testing composition having 1.8-2.2 w/v% bimethylbenzaldehyde, 20.0v/v% concentrated hydrochloric acid, 5.0 v/v% acetic acid and a remaining quantity of distilled water, and

an amylase testing composition having 0.34 w/v% iodine, 0.68w/v% potassium iodide, 1 v/v% glycerol and a remaining quantity of distilled water; and

a second corresponding plurality of interpretation spectra with respect to said bilirubin testing composition, said bilinogen testing composition, and said amylase testing composition respectively, wherein each said testing composition of said second plurality of testing compositions in response to a testing sample reacts to the testing sample providing a result such that a user is capable of comparing the result and said second corresponding spectrum to generate second health condition data.

Claim 22 (new): The medical test kit, as recited in claim 21, further comprising:

a ketone testing composition having 1.24 w/w% sodium nitrofericyanide, 37.04 w/w% anhydrous sodium carbonate, and 61.73 w/w% sulfamine; and

a pH testing composition having 0.01 w/v% phenyl red and a remaining quantity of distilled water; and

a third corresponding plurality of interpretation spectra with respect to said ketone testing composition and said pH testing composition respectively, wherein each of said third composition in response to a testing sample reacts to the testing sample for providing a result such that a user is capable of comparing the result and said third corresponding spectrum to generate third health condition data.

Claim 23 (new): The medical test kit, as recited in claim 22, further comprising a dynamic recordation diagram which has an interpretation spectrum, and is arranged to record said first through third health condition data obtained from each of said first, said second and said third testing compositions, wherein a user is able to compare said first

through third health condition data with said dynamic recordation diagram and categorize said first through third health condition data into at least three categories which are healthy condition, doubt condition, and unhealthy condition according to said interpretation spectrum, wherein said dynamic recordation diagram is also adapted for recording said first through third health condition data from said first, said second, and said third compositions respectively.

Claim 24 (new): The medical test kit, as recited in claim 23, further comprising an interactive reference chart having a self assessment portion, a suggested test portion, and a possible illnesses portion wherein said self assessment portion provides information on common symptoms with respect to possible illnesses, wherein said suggested test portion provides a suggestion of said first through third testing compositions with respect to said common symptoms, such that a user is capable of selecting at least one testing composition from said first through third testing compositions according to a symptom of said user and guidance from said interactive reference chart.

Claim 25 (new): The medical testing kit, as recited in claim 24, wherein said interpretation spectrum of said glucose testing composition has an effective glucose concentration range between 0.03% and 2%, wherein said interpretation spectrum of said protein testing composition has an effective protein concentration range between 0.004% and 0.5%, wherein said interpretation spectrum of said bilirubin testing composition has an effective bilirubin concentration range between 0.125% and 1%, wherein said interpretation spectrum of said bilinogen testing composition has an effective bilinogen concentration range which represents a bilinogen concentration higher than 0.05 and for bilinogen concentration lower than 0.05, wherein said interpretation spectrum of said amylase testing composition has an effective range that at least represents a normal condition, a over active condition, and an inactive condition; wherein said interpretation spectrum of said blood testing composition has an effective blood concentration range between 0.015% and 0.5%, wherein said interpretation spectrum of said calcium testing composition has an effective calcium concentration range between 0.012% and 0.2%, and wherein said interpretation spectrum of said nitrite testing composition has an effective nitrite concentration range between 0.00015% and 0.005%.

Claim 26 (new): The medical testing kit, as recited in claim 24, wherein said interpretation spectrum of said glucose testing composition has an effective glucose concentration range between 0.03% and 2% represented by a color range from pale blue, green, yellow, to brown, wherein said interpretation spectrum of said protein testing composition has an effective protein concentration range between 0.004% and 0.5% represented by a color range from little trace white precipitation to heavily white precipitation, wherein said interpretation spectrum of said bilirubin testing composition has an effective bilirubin concentration range between 0.125% and 1% represented by a color range from pale blue green to blue green, wherein said interpretation spectrum of said bilinogen testing composition has an effective bilinogen concentration range which represents a bilinogen concentration higher than 0.05 and for bilinogen concentration lower than 0.05 represented by a color ranged from red to colorless, wherein said interpretation spectrum of said amylase testing composition has an effective amylase concentration range representing a normal condition, an over active condition, and an inactive condition, wherein said interpretation spectrum of said blood testing composition has an effective blood concentration range between 0.015% and 0.5%, wherein said interpretation spectrum of said calcium testing composition has an effective calcium concentration range between 0.012% and 0.2% represented by a color ranged from slight opacity to milky precipitation, and wherein said interpretation spectrum of said nitrite testing composition has an effective nitrite concentration range between 0.00015% and 0.005% represented by a color ranged from cherry-red to dark cherry-red respectively.

Claim 27 (new): The medical testing kit, as recited in claim 25, further comprising a plurality of testing tubes corresponding to each of said testing compositions respectively.

Claim 28 (new): The medical testing kit, as recited in claim 26, further comprising a plurality of testing tubes corresponding to each of said testing compositions respectively.

Claim 29 (new): A method of preparing a medical testing kit, comprising the steps of:

(a) providing a glucose testing composition by reacting 9.8-17.3 w/v% sodium citrate, 5.3-10.0 w/v% anhydrous sodium carbonate, 1.5-1.73 w/v% copper sulfate and a remaining quantity of distilled water to form said glucose testing composition;

(b) providing a protein testing composition by reacting 9.4-10.5 w/v% salicylic sulfate, 38-50 ml distilled water in 100 ml protein testing composition, 0.5-2.0 w/v% sodium chloride, 1.0-3.0 v/v% anhydrous acetic acid and a remaining quantity of 95% methanol to form a protein testing composition;

(c) providing a blood testing composition by reacting 0.25-1.0 w/v% benzidine, 40-80 ml acetic acid in 100 ml of said blood testing composition, and a remaining quantity of 95% methanol to form a blood testing composition;

(d) providing a calcium testing composition by reacting 1.5-2.0 w/v% oxalic acid, 1.5-2.0 w/v% oxalic amide, 3.2-3.5 v/v% acetic acid and a remaining quantity of distilled water to form a calcium testing composition; and

(e) providing a nitrite testing composition by reacting 0.35-0.45 w/v% sulfanilic acid, 0.2-0.3 w/v% α-naphthyl amide, 1.0-2.0 v/v% methanol, 20-40.0 v/v% acetic acid and a remaining quantity of distilled water to form a nitrite testing composition; and

(f) providing a corresponding number of first interpretation spectra for said glucose testing composition, said protein testing composition, said blood testing composition, said calcium testing composition and said nitrite testing composition respectively such that results obtained from said testing compositions are capable of representing a health condition of said user.

Claim 30 (new): The method, as recited in claim 29, further comprising the steps of:

(g) providing a bilirubin testing composition by reacting 0.89-1.2 w/v% acid iron chloride, 20.0-25.3 w/v% acetate chloride, 5.0 ml acetic acid in each 100 ml bilirubin testing composition, and a remaining quantity of distilled water to form said bilirubin testing composition;

(h) providing a bilinogen testing composition by reacting 1.8-2.2 w/v% bimethylbenzaldehyde, 20.0v/v% concentrated hydrochloric acid, 5.0 v/v% acetic acid and a remaining quantity of distilled water to form a bilinogen testing composition; and

(i) providing an amylase testing composition by reacting 0.34 w/v% iodine, 0.68w/v% potassium iodide, 1 v/v% glycerol and a remaining quantity of distilled water to form said amylase testing composition, and

(j) providing a corresponding number of second interpretation spectra with respect to said bilirubin testing composition, said bilinogen testing composition, and said amylase testing solution such that results obtained from said bilirubin testing composition, said bilinogen testing composition, and said amylase testing solution are capable of representing a health condition of said user.

Claim 31 (new): The method, as recited in claim 12, further comprising the steps of:

(k) providing a ketone testing composition by reacting 1.24 w/w% sodium nitrofericyanide, 37.04 w/w% anhydrous sodium carbonate, and 61.73 w/w% sulfamine to form said ketone testing composition; and

(l) providing a pH testing composition by diluting 0.01 w/v% phenyl red with a remaining quantity of distilled water to form said pH testing composition, wherein with respect to said third plurality of testing compositions,

(m) providing a corresponding number of interpretation spectra with respect to said ketone testing composition and pH testing composition such that results obtained from said ketone testing composition and pH testing composition are capable of representing a health condition of said user.

Claim 32 (new): The method, as recited in claim 31, further comprising a step of analyzing said results with a dynamic recordation diagram, wherein said dynamic recordation diagram has a plurality of sections with respect to each said testing compositions, and each section has at least three portions representing a healthy condition category, a doubt condition category, and an unhealthy condition category respectively.

Claim 33 (new): The method, as recited in claim 32, further comprising a step of selecting said testing compositions in response to an interactive reference chart, wherein the interactive reference chart has a self assessment portion, a suggested test portion, and a possible illnesses portion, wherein said self assessment portion provides common symptoms with respect to possible illnesses and said suggested test portion provides a suggestion of said testing compositions of said medical test kit with respect to the common symptoms such that a user is capable of selecting a correct testing composition.

Claim 34 (new): The method, as recited in claim 33, wherein said interpretation spectrum of said glucose testing composition has an effective glucose concentration range between 0.03% and 2%, wherein said interpretation spectrum of said protein testing composition has an effective protein concentration range between 0.004% and 0.5%, wherein said interpretation spectrum of said bilirubin testing composition has an effective bilirubin concentration range between 0.125% and 1%, wherein said interpretation spectrum of said bilinogen testing composition has an effective bilinogen concentration range which represents a bilinogen concentration higher than 0.05 and for bilinogen concentration lower than 0.05, wherein said interpretation spectrum of said amylase testing composition has an effective range that at least represents a normal condition, a over active condition, and an inactive condition; wherein said interpretation spectrum of said blood testing composition has an effective blood concentration range between 0.015% and 0.5%, wherein said interpretation spectrum of said calcium testing composition has an effective calcium concentration range between 0.012% and 0.2%, and wherein said interpretation spectrum of said nitrite testing composition has an effective nitrite concentration range between 0.00015% and 0.005%.

Claim 35 (new): The method, as recited in claim 33, wherein said interpretation spectrum of said glucose testing composition has an effective glucose concentration range between 0.03% and 2% represented by a color range from pale blue, green, yellow, to brown, wherein said interpretation spectrum of said protein testing composition has an effective protein concentration range between 0.004% and 0.5% represented by a color range from little trace white precipitation to heavily white precipitation, wherein said interpretation spectrum of said bilirubin testing composition has an effective bilirubin concentration range between 0.125% and 1% represented by a color range from pale blue green to blue green, wherein said interpretation spectrum of said bilinogen testing composition has an effective bilinogen concentration range